US RE49,647 E1
Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Darshan Parikh, Bridgewater, NJ (US); and Anil Menon, Martinsville, NJ (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US)
Filed on Sep. 23, 2020, as Appl. No. 17/30,272.
Application 17/030,272 is a reissue of application No. 14/508,719, filed on Oct. 7, 2014, granted, now 10,080,801, issued on Sep. 25, 2018.
Claims priority of provisional application 61/888,419, filed on Oct. 8, 2013.
Int. Cl. A61K 47/26 (2006.01); A61K 9/48 (2006.01); A61K 31/5377 (2006.01)
CPC A61K 47/26 (2013.01) [A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/5377 (2013.01); Y02A 50/30 (2018.01)] 37 Claims
 
8. An oral dosage form which weighs about 75 mg and comprises: 1) Compound A of the following structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.3 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient [ at an amount of about 90 to about 99.9 weight percent of total weight of the oral dosage form] , wherein the carrier or excipient is a mixture of starch and lactose [ , and wherein the weight ratio of lactose to starch in the oral dosage form is from 2.1:1 to 3.9:1] ; and 3) a lubricant [ , at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, ] wherein the lubricant is stearic acid.